Lucid Diagnostics Inc. LUCD
0.42 USD +0.03 (+9.15%)
At closeNov 12, 2026, 5:14 PM EST
0.40 -0.01 -3.58%
After hours · Nov 12, 5:14 PM ET
0.3826 Day range 0.43
0.303 52-week range 1.63
- YTD
- -61.81%
- 1 year
- -62.50%
News
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Oragenics (AMEX:OGEN) stock increased by 30.2% to $0.46 during Thursday's after-market session. The market value of their outstanding shares is at $1.5 million. InspireMD (NASDAQ:NSPR) shares…
marketbeat.com What Lucid Diagnostics (LUCD) Said on Its Q3 Earnings Call Lucid Diagnostics NASDAQ: LUCD said Medicare payments for its EsoGuard esophageal pre-cancer test have begun through its Texas laboratory, prompting the company to redirect its sales efforts toward…
seekingalpha.com Lucid Diagnostics Inc. (LUCD) Q3 2026 Earnings Call Transcript Lucid Diagnostics Inc. (LUCD) Q3 2026 Earnings Call Transcript
zacks.com Lucid Diagnostics Inc. (LUCD) Reports Q3 Loss, Lags Revenue Estimates Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.1 per share a year ago.
benzinga.com Lucid Diagnostics Q3 Adj. EPS $(0.06), Inline, Sales $1.203M Miss $1.635M Estimate Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 40 percent increase over losses of $(0.10) per share from the same…
zacks.com Mettler-Toledo (MTD) Surpasses Q3 Earnings and Revenue Estimates Mettler-Toledo (MTD) came out with quarterly earnings of $12.57 per share, beating the Zacks Consensus Estimate of $12.11 per share. This compares to earnings of $11.15 per share a year ago.
prnewswire.com Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed…
benzinga.com PAVmed Unit Lucid Diagnostics Announces Publication Of Clinical Findings From Nonendoscopic Esophageal Precancer Testing Using The EsoGuard; Study Demonstrates Efficiency And Scalability Of EsoCheckCell Collection In Under Two Minutes The manuscript, "Non-Endoscopic Screening for Barrett's Esophagus Using a DNA Methylation-Based Assay: Real-World Experience in 11,991 Patients," published in the journal Diagnostics, reported that…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 58.8% to $6.65 during Friday's regular session. The market value of their outstanding shares is at $7.9 million. Lucid Diagnostics…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…
benzinga.com Why RingCentral Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket RingCentral surged 15% after beating Q3 estimates and raising FY26 guidance; XXII, LABT and HUBC led premarket gainers, while LNAI fell.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics…- benzinga.com Lucid Diagnostics Receiving Medicare Payments For Its EsoGuard Esophageal DNA Test; Closed $15M Private Placement Of Its Newly Designated Series C Convertible Prefs To Existing Long-Term Shareholders On October 21 On September 22, Lucid announced that it would begin submitting Medicare claims for EsoGuard tests performed at one of its two CLIA-certified laboratories. Shortly thereafter, the Company began…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Elutia (NASDAQ:ELUT) stock moved upwards by 17.2% to $0.94 during Thursday's after-market session. The market value of their outstanding shares is at $34.9 million. Intelligent Bio Solutions…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Nexalin Technology (NASDAQ:NXL) shares increased by 77.8% to $7.61 during Thursday's regular session. The company's market cap stands at $3.5 million. Stablecoin Development (AMEX:SDEV) stock…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers IM Cannabis (NASDAQ:IMCC) stock rose 108.5% to $3.63 during Friday's pre-market session. The market value of their outstanding shares is at $1.0 million. Alaunos Therapeutics (NASDAQ:TCRT)…
- benzinga.com Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.5 Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $9.25 to $9.5.
benzinga.com Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says Lucid Diagnostics confirmed its first LBM win with Concert, opens up 10M covered lives. Analyst maintains Buy rating and $2.50 PT.- benzinga.com Lucid Diagnostics Q2 2026 Earnings Call: Complete Transcript Lucid Diagnostics (NASDAQ:LUCD) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For…
benzinga.com Lucid Diagnostics Q2 Adj. EPS $(0.08) Misses $(0.07) Estimate, Sales $1.474M Miss $1.943M Estimate Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 33.33 percent. This is a 20 percent increase over losses of…
benzinga.com Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case Lucid Diagnostics reported Q1 revenue miss. Analyst significant expects revenue growth in 2026/27. Raises PT to $9.25.
benzinga.com Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.25 Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $9 to $9.25.
benzinga.com Maxim Group Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2 Maxim Group analyst Anthony Vendetti maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and lowers the price target from $3 to $2.
benzinga.com Lucid Diagnostics Q1 Adj. EPS $(0.07) Beats $(0.08) Estimate Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 56.25 percent increase over losses of…
benzinga.com Earnings Scheduled For May 14, 2026 - benzinga.com Lucid Diagnostics Q1 Sales $1.256M Miss $1.383M Estimate Lucid Diagnostics (NASDAQ:LUCD) reported quarterly sales of $1.256 million which missed the analyst consensus estimate of $1.383 million by 9.18 percent. This is a 57.00 percent increase over sales…
benzinga.com Lucid Diagnostics Prices Underwritten Registered Direct Offering Of 18M Common Shares At $1.00 Per Share Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the…
benzinga.com Texas Instruments To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday Top analysts change outlook on top names, like AA, SSSS, TXN, HQY, LUCD, RPM, PAR, ASRT. Morgan Stanley raised AA target, Ascendiant raised LUCD.
benzinga.com Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9 Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $8.25 to $9.- benzinga.com Lucid Diagnostics Q4 Adj. EPS $(0.10), Inline, Sales $1.504M Beat $1.379M Estimate Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 47.37 percent increase over losses of $(0.19) per share from the…
- benzinga.com Earnings Scheduled For March 26, 2026
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com What's Going On With PAVmed Shares Thursday? PAVmed shares pull back Thursday, possibly retracing recent gains on news its subsidiary, Lucid Diagnostics secured a contract
benzinga.com Why Is PAVmed Stock Skyrocketing Wednesday? PAVmed Inc. (PAVM) surges as its subsidiary Lucid Diagnostics (LUCD) secures a contract with VA for its cancer prevention test.- benzinga.com Lucid Diagnostics Wins VA Contract For EsoGuard, Expanding Esophageal Cancer Screening Across Nationwide VA Healthcare System Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it…
- benzinga.com Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $8.25 Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $8 to $8.25.
- benzinga.com Lucid Diagnostics Files Prospectus To Raise Up To $175M Through Sale Of Stock, Debt And Warrants Lucid Diagnostics Inc. $175,000,000 Common Stock, Preferred Stock, Debt Securities, Warrants and Units We may offer and sell from time to time shares of common stock, shares of preferred stock, debt
- benzinga.com Lucid Diagnostics Q3 Adj. EPS $(0.10) Beats $(0.11) Estimate, Sales $1.211M Miss $1.357M Estimate Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 50 percent increase over losses of…
- benzinga.com Earnings Scheduled For November 12, 2025
- benzinga.com Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $8 Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $7.75 to $8.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target BTIG analyst Mark Massaro reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Lucid Diagnostics Announces $25M Public Offering Of 25M Shares Of Common Stock At A Price Of $1.00/Share Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com Lucid Diagnostics Reveals Proposed Public Offering of Common Stock; Size Not Disclosed NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed…
- benzinga.com BTIG Maintains Buy on Lucid Diagnostics, Raises Price Target to $2.5 BTIG analyst Mark Massaro maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $2 to $2.5.